(Q37734219)

22 August 2017

1 reference

title

Adjunct therapy for type 1 diabetes mellitus (English)

1 reference

22 August 2017

0 references

Harold E Lebovitz

1

1 reference

22 August 2017

publication date

20 April 2010

1 reference

Nature Reviews Endocrinology

22 August 2017

published in

1 reference

22 August 2017

volume

6

1 reference

22 August 2017

issue

6

1 reference

22 August 2017

page(s)

326-334

1 reference

Localized glucoprivation of hindbrain sites elicits corticosterone and glucagon secretion

22 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Adverse events and their association with treatment regimens in the diabetes control and complications trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complicat

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The metabolic syndrome in type 1 diabetes: does it exist and does it matter?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Metabolic syndrome as a risk factor for cardiovascular disease, mortality, and progression of diabetic nephropathy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion in IDDM patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Beta-cell-mediated signaling predominates over direct alpha-cell signaling in the regulation of glucagon secretion in humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The nucleus tractus solitarius: a portal for visceral afferent signal processing, energy status assessment and integration of their combined effects on food intake

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Relationship between oral glucose tolerance and gastric emptying in normal healthy subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Importance of changes in gastric emptying for postprandial plasma glucose fluxes in healthy humans

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Serum glucose concentration as a modulator of interdigestive gastric motility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Hyperglycaemia slows gastric emptying in type 1 (insulin-dependent) diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Hypoglycaemia increases the gastric emptying rate in patients with type 1 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Impaired hyperglycemia-induced delay in gastric emptying in patients with type 1 diabetes deficient for islet amyloid polypeptide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Co-secretion of amylin and insulin from cultured islet β-cells: Modulation by nutrient secretagogues, islet hormones and hypoglycemic agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Amylin agonists: a novel approach in the treatment of diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Amylin receptors: molecular composition and pharmacology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Comparison of Fos induced in rat brain by GLP-1 and amylin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Lesion of the area postrema/nucleus of the solitary tract (AP/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Clinical implications of amylin and amylin deficiency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pharmacokinetics and pharmacodynamics of AC137 (25,28,29 tripro-amylin, human) after intravenous bolus and infusion doses in patients with insulin-dependent diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Low-dose pramlintide reduced food intake and meal duration in healthy, normal-weight subjects

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide, an amylin analog, selectively delays gastric emptying: potential role of vagal inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The role of amylin and glucagon in the dampening of glycemic excursions in children with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Evidence for an important role of glucagon in the regulation of hepatic glucose production in normal man.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide Reduces Postprandial Glucose Excursions When Added to Regular Insulin or Insulin Lispro in Subjects With Type 1 Diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Effects of pramlintide on postprandial glucose excursions and measures of oxidative stress in patients with type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Effect of adjunctive pramlintide treatment on treatment satisfaction in patients with type 1 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type 1 diabetes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Twenty-four-hour simultaneous subcutaneous Basal-bolus administration of insulin and amylin in adolescents with type 1 diabetes decreases postprandial hyperglycemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Pramlintide in pediatric type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

alpha-Glucosidase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Alpha-glucosidase inhibition as an adjunct to the treatment of type 1 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Acarbose in the treatment of type I diabetes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo-controlled,double-blind, multicentre study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The use of metformin in type 1 diabetes: a systematic review of efficacy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.49

Relationships between gastric emptying, intragastric meal distribution and blood glucose concentrations in diabetes mellitus

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20404854

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Impact of lack of suppression of glucagon on glucose tolerance in humans

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20404854

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High affinity amylin binding sites in rat brain

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20404854

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRENDO.2010.49

1 reference

22 August 2017

1 reference